{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:44Z","timestamp":1787070884676,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Imatinib is a tyrosine kinase inhibitor that selectively inhibits several protein tyrosine kinases which is central to the pathogenesis of human cancer. It forms the first-line treatment for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. Usually, the drug is well-tolerated with relatively few side effects. Adverse effects most commonly associated with imatinib include mild-to-moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions. Other side effects such as the elevation of hepatic transaminase and myelosuppression occur less frequently and resolve with interruption of imatinib therapy. Skin rash is one of the most common adverse effects of imatinib incidence of which range from 7% to 88.9%. Exfoliative dermatitis, i.e., erythroderma has been very rarely reported with this drug. We here report a rare case of erythroderma in a patient with CML on imatinib 400 mg\/day therapy within 3 months of starting the treatment.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_306_18","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:31:54Z","timestamp":1674815514000},"page":"253-256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Erythroderma: An unusual manifestation of imatinib \u2013 A rare case report"],"prefix":"10.4103","volume":"18","author":[{"given":"Pritam","family":"Kataria","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Kendre","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahush","family":"Tahiliani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Mule","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza","family":"Bohra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"R1-20250510","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: A review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"R2-20250510","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2004.03.038","article-title":"Molecularly targeted treatment for dermatofibrosarcoma protuberans","volume":"31","author":"McArthur","year":"2004","journal-title":"Semin Oncol"},{"key":"R3-20250510","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"R4-20250510","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semarthrit.2012.06.001","article-title":"Therapeutic inhibition of tyrosine kinases in systemic sclerosis: A review of published experience on the first 108 patients treated with imatinib","volume":"42","author":"Bournia","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20250510","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"R6-20250510","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ad.2011.10.019","article-title":"KIT mutations in a series of melanomas and their impact on treatment with imatinib","volume":"103","author":"Botella-Estrada","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"R7-20250510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: Long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch Toxicol"},{"key":"R8-20250510","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-20250510","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-20250510","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00520-008-0536-8","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"key":"R11-20250510","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R12-20250510","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R13-20250510","first-page":"538","article-title":"Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism","volume":"17","author":"Vano-Galvan","year":"2007","journal-title":"Eur J Dermatol"},{"key":"R14-20250510","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R15-20250510","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors \u2013 A review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_306_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:14Z","timestamp":1787067494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_306_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_306_18","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2018-05-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}